The startup develops biosensor technologies that enable the analysis of proteins and small molecules in pharmaceutical research and manufacturing. Its diagnostic analyzers and kits facilitate rapid and sensitive biomolecular interaction assessments, providing near real-time medical diagnostics for researchers.

Acrobat focuses on advancing human health through genomic solutions. The company leverages genomic technologies to develop new approaches in the life sciences sector. Their work aims to provide tools and insights that support health and biological research.

This company develops vaccines and therapies targeting aging and age-related diseases by leveraging artificial intelligence. They integrate extensive biological and clinical data, including information on cancers, drugs, and proteins, to accurately predict effective combination therapies. Their approach aims to create preventative vaccines for chronic diseases, potentially extending human healthspan.

The startup has developed a cell preservation technology that utilizes alginate hydrogels to encapsulate cells and tissues, allowing for safe storage and transport at room temperature. This method protects biological products from biochemical and physical damage, ensuring their viability for medical use.

Bounce Imaging provides lightweight, throwable 360° tactical cameras that deliver real‑time omnidirectional video and two‑way audio to any iOS or Android device via Wi‑Fi or 4G/LTE. Designed for first‑responders, law‑enforcement, and military teams, the rugged devices can be tossed, lowered on a tether, or mounted on a pole to quickly visualize confined or hazardous spaces, improving situational awareness and officer safety.

C2sense offers algorithmic software that enhances the sensitivity and specificity of point‑of‑care and at‑home diagnostic assays without changing the underlying chemistry. Their platform detects hundreds to thousands of targets at single‑copy sensitivity in under three hours using standard lab equipment, delivering up to ten‑fold sensitivity gains and rapid false‑positive mitigation. Custom analytical solutions are typically deployed within a week, helping test manufacturers improve performance and accelerate time‑to‑market.

CloudCath has developed a hardware-enabled digital platform that utilizes optical analysis to monitor turbidity in discarded dialysate fluid from peritoneal dialysis patients, providing real-time insights to healthcare providers. This technology addresses the critical issue of peritonitis by enabling early detection of complications, potentially improving patient outcomes and reducing hospitalizations.

Cordance Medical is developing the NeuroAccess™ system, a non-invasive ultrasound device that reversibly opens the blood-brain barrier using low-frequency focused ultrasound and microbubbles. This technology enables targeted delivery of therapeutics and diagnostic biomarkers to the brain, addressing the challenge of drug delivery for conditions such as brain cancers, Alzheimer's, and Parkinson's disease.

The startup develops gene editing technology that directs cells to utilize error-free repair pathways, minimizing cellular toxicity while enabling large genomic edits. This approach aims to create genetic cures for liver and pancreatic diseases by addressing the challenges of precise DNA manipulation for therapeutic applications.

Exogene utilizes a generative AI platform to mine the T-cell receptor (TCR) sequence space for novel, high-affinity TCRs. This technology addresses the difficulty of identifying effective TCRs against cancer targets using traditional discovery methods. The company aims to unlock curative TCR-based immunotherapies for solid tumor eradication.

The startup develops a micro-optic sperm testing device that enables men to assess their fertility at home by measuring sperm quality. Utilizing artificial intelligence, the device provides personalized lifestyle intervention supplements based on scientifically researched data, empowering users to enhance their reproductive health.

Genomelink allows users to upload raw DNA data from services like AncestryDNA, 23andMe, or MyHeritage for enhanced genetic analysis, providing insights into ancestry, health, and personal traits. This platform addresses the lack of detailed genetic information by offering over 350 unique traits and specialized reports that are not available through standard DNA testing services.

GTcardio provides the CALM™ platform, a non-invasive bio-sensing technology for continuous hemodynamic monitoring. It measures blood pressure and SpO2 using photoplethysmography (PPG) to analyze blood circulation dynamics, offering personalized insights for proactive cardiovascular health management.

Provides a mobile AI-powered traffic enforcement platform that uses deep learning and edge processing to automatically monitor and enforce bus lane and bus stop regulations. By collecting and analyzing vision-based data, it improves transit safety and efficiency while prioritizing data privacy through encryption and selective storage.

Healx utilizes generative AI to enhance and combine existing compounds for the rapid discovery of treatments for rare diseases, addressing the lack of effective therapies for over 90% of the 10,000 known rare diseases. By de-risking the drug development process, Healx increases the likelihood of successful outcomes and accelerates the delivery of new therapies to patients.

Introhive offers an AI-powered Client Intelligence Platform that automates the capture and enrichment of client data, providing actionable insights into relationship networks. This technology addresses the challenges of fragmented client information and manual data entry, enabling B2B enterprises to enhance lead generation, improve win rates, and increase productivity.

KetoSwiss is a Swiss-based biotech startup that develops ketone body supplements to provide an alternative energy source for individuals with metabolic disorders. Their product, MigraKet, specifically targets migraine management by utilizing the neuroprotective properties of ketones to alleviate symptoms.

Melio is developing a rapid blood testing platform that utilizes proprietary assays and microfluidics to identify pathogens within hours, significantly reducing the time required for diagnosis compared to traditional blood cultures. This technology addresses the critical need for timely and accurate detection of bloodborne infections, particularly for vulnerable populations such as newborns in the NICU.

The startup develops a fasting mimetic that utilizes a specific combination of bioactive human metabolites to replicate the cellular health benefits of fasting. This approach provides anti-inflammatory and antioxidant effects, addressing age-associated chronic inflammation and cellular damage without the need for actual fasting.

The startup develops a light detection and ranging (LiDAR) vision system that enhances driver safety and vehicle autonomy by providing precise distance measurement and wide field of view capabilities. Their technology aims to reduce automotive accidents and fatalities while offering scalable and cost-effective optical measurement solutions for various industrial applications.

The startup specializes in mitochondrial transfusion therapy to combat age-related diseases such as Alzheimer's and Parkinson's. By enhancing mitochondrial function, the company aims to improve healing processes and reduce frailty in elderly patients and wounded soldiers.

NeuroAge Therapeutics provides comprehensive AI-powered cognitive testing that integrates online assessments, blood biomarkers, genetics, and MRI data. This analysis determines an individual's brain aging rate to assess future risk for neurodegenerative diseases like Alzheimer's and Parkinson's. The company then delivers personalized recommendations aimed at slowing brain aging and developing tailored therapeutics for neurodegeneration.

Oxford Drug Design uses AI and machine‑learning combined with deep expertise in tRNA synthetase biology to accelerate the discovery of novel therapeutics for cancer and other major diseases. Their platform integrates structural data, predictive modeling, and automated virtual screening to rapidly generate and optimize drug candidates with improved potency, selectivity, and safety, offering pharmaceutical and biotech partners a faster, more efficient path to targeted therapies.

PanTher Therapeutics develops a polymer-based drug delivery system that enables high-dose, localized chemotherapy directly at tumor sites, significantly increasing drug concentration while minimizing systemic exposure. This approach addresses the limitations of traditional chemotherapy by providing continuous therapeutic levels over extended durations, enhancing treatment efficacy with reduced side effects.